Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Emopamil-binding protein-like (EBPL) is a human protein encoded by the EBPL gene on chromosome 13q14.2. It shares moderate sequence homology with emopamil-binding protein (EBP), a known sterol delta8-delta7 isomerase involved in cholesterol biosynthesis. Unlike EBP, EBPL lacks detectable sterol isomerase and sigma-ligand binding activity, as confirmed by heterologous expression studies and functional analyses. Most residues required for isomerase activity are conserved in EBPL, but key differences preclude catalytic function. EBPL is ubiquitously expressed, with highest mRNA levels in liver, lung, and kidney. Frameshift mutations in EBPL have been detected in microsatellite unstable tumors; resultant neopeptides are rapidly degraded via the proteasome, suggesting the protein is tightly regulated. The physiological function of EBPL remains unknown, and it has not been linked to specific diseases or therapeutic agents. The protein is classified as "other" in molecular terms due to its unclear function and lack of canonical receptor, enzyme, transporter, or transcription factor activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Emopamil-binding protein-like (EBPL).